Recruiting
Haematological malignancy+1
RecruitingInvestigationalNo placebo
Study on the Safety and Effectiveness of SMART101 for Patients Undergoing Stem Cell Transplantation for Blood Cancers
InvestigationalNo placebo
- Disease:Haematological malignancyAllogenic stem cell transplantation
- Substances:Allogeneic T-Cell Precursors, Mobilized Peripheral Blood-Derived, Ex Vivo Cultured
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Allogeneic T-Cell Precursors, Mobilized Peripheral Blood-Derived, Ex Vivo Cultured
- Sponsor:Smart Immune














